All Posts Tagged With: "AZN"
(MAA) Roche Holdings’ Skin Cancer Drug Impresses
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual...
(AFFX) Company News for June 03, 2011 – Corporate Summary
• Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038...
(AZN) AstraZeneca Revenues Fall – Outlook Improves
AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter....
(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing...
(DNDN) Dendreon Learns Medicare May Pay for Provenge Prostate Cancer Vaccine
Dendreon Corporation (DNDN) received a huge boost today when the Centers for Medicare and Medicaid Services (CMS) proposed to pay for its lead prostate cancer vaccine Provenge.
Provenge was approved...
(AZN) AstraZeneca Drug Vandetanib Earns FDA Approval
AstraZeneca (AZN) recently gained US Food and Drug Administration (FDA) approval for its orphan drug vandetanib for the treatment of non-operable (unresectable) locally advanced or metastatic medullary thyroid...
(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on...
(DNDN) Dendreon Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $39.00 following the announcement of fourth quarter and full year 2010 financial results.
Dendreon’s...
(PDLI) PDL BioPharma Ramps Up Earnings – Settles Disputes
PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a...
(AZN) AstraZeneca Announces Response to FDA Complete Response Letter
AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided...
(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab
AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease.
The...
(AZN) AstraZeneca Suffers FDA Regulatory Setback
AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the...
(ACN) Company News for December 17, 2010 – Corporate Summary
• Oracle (NASDAQ:ORCL) reported fiscal second quarter earnings of $0.51, beating the Zacks Consensus Estimate of $0.44, on revenues of $8.6 billion that topped the Zacks Consensus Estimate of $8.3 billion
• Take-Two...
(BMY) Bristol-Myers Squibb Beats Expectations on EPS – Misses on Sales
Bristol-Myers Squibb Company’s (BMY) third quarter 2010 earnings (excluding special items) of $0.59 per share surpassed the Zacks Consensus Estimate by $0.06. The company had earned $0.47 per share in the...
(REGN) Regeneron Pharmaceuticals Quarterly Loss Wider than Expected
Regeneron Pharmaceuticals Inc.‘s (REGN) third quarter 2010 net loss of 41 cents per share was wider than the Zacks Consensus Estimate of a net loss of 34 cents. The company suffered a loss of 1 cent...
(BMY) Bristol-Myers Squibb’s Pipeline Advances
Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind,...
(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data
Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group,...
(AZN) AstraZeneca Receives Positive European Union Opinion for Drug
AstraZeneca (AZN) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Brilique (ticagrelor). The company is seeking approval in the EU for the use of Brilique...
(BMY) Bristol-Myers Squibb Company Diabetes Drug Candidate Encourages
Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, international, randomized, parallel-group,...
(ABT) Abbott Labs Announces Aquisition of Indian Company Piramal Healthcare
Abbott Labs (ABT) recently completed its acquisition of Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.8 billion. In addition to an...
(AZN) Growing Chinese Pharmaceutical Market is Opportunity
by Tony D’Altorio, Investment U Research
Thursday, September 9,...
(PDLI) PDL BioPharma Announces Third-Quarter Outlook
PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third-quarter 2010 (ending September 30) revenue of $86.0 million, representing an increase of 20% over the year-ago...
(MDVN) Medivation 2010 Second Quarter Earnings Narrow Loss
Medivation Inc. (MDVN) reported a loss of 21 cents per share in the second quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 29 cents. Lower expenses...
(REGN) Regeneron Pharmaceuticals’ Quarterly Loss Narrower than Expected
Regeneron Pharmaceuticals Inc.’s (REGN) second-quarter 2010 net loss of $25.5 million, or 31 cents per share, was narrower than the Zacks Consensus Estimate of a net loss of 38 cents. The company suffered...
(BMY) Bristol-Myers Squibb Reports Encouraging Diabetes Therapy Data
Recently, Bristol-Myers Squibb Co. (BMY) reported encouraging results from a late-stage study evaluating the combination therapy of Onglyza (saxagliptin) and metformin in patients suffering from type II diabetes....
(TEVA) Teva Pharmaceutical Industries Settles with AstraZeneca
Teva Pharmaceutical Industries (TEVA) recently entered into an agreement with AstraZeneca (AZN) to settle their litigation regarding the...
(MDVN) Medivation Quarterly Report Shows Wider Loss
Medivation Inc. (MDVN) reported a loss of 51 cents per share in the first quarter of 2010, exceeding the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 19 cents. Lower revenues and...
(REGN) Regeneron Pharmaceuticals Reports Narrower-Than-Forecasted Loss
Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4...
(REGN) Regeneron Pharmaceutical’s First Quarter Earnings Loss Narrower
Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4...
(POZN) Pozen’s Announces That FDA Approves Vimovo
On April 30, 2010, Pozen (POZN) and its partner, AstraZeneca (AZN), announced that the U.S. Food and Drug Administration (FDA) has approved...